At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 3 clinical trial evaluating Calaspargase Pegol-mknl, Cyclophosphamide, and 13 other interventions for Acute Lymphoblastic Leukemia and 2 related conditions. Completed, enrolled 166 participants across 27 sites.
Detailed Summary
This randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together with combination chemotherapy in treating younger patients with newly diagnosed high-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV, IT, PO, or SC
Given IV
Given PO or IV
Given IV
Correlative studies
Given PO
Given IV, IT, or PO
Given IV
Correlative studies
Given IV or PO
Some patients undergo RT
Given PO
Given IV